Effects of upconversion nanoparticles with a thermo-responsive nanovalve loaded with doxorubicin in melanoma cells

  • Melanoma skin cancer has an increasingly higher incidence , and w hen detected in advanced stages, tumour eradication is often incomplete, contributing to poor prognosis with conventional treatments. Upconversion nanoparticles (UCNPs) have unique properties, such as excitability under near infrared (NIR) excitation light, which confers a relatively high penetration depth in tissue that allow their effective use in several biomedical applications Mesoporous silica nanoparticles (MSN) with nanovalves or derived coatings have widely been used for triggered and targeted drug delivery in the past. Anticancer drugs can be loaded into the pores of MSN, enabling controlled drug release. In this work, UCNPs were coated with a mesoporous silica shell yielding UCNP@MSN core shell nanoparticles which were equipped with thermoresponsive retro Diels Alder nanovalves and then loaded with DOX , a chemotherapeutic agent for melanoma treatmen t (UCNP@MSN DOX) Subsequent DOX release from this drugMelanoma skin cancer has an increasingly higher incidence , and w hen detected in advanced stages, tumour eradication is often incomplete, contributing to poor prognosis with conventional treatments. Upconversion nanoparticles (UCNPs) have unique properties, such as excitability under near infrared (NIR) excitation light, which confers a relatively high penetration depth in tissue that allow their effective use in several biomedical applications Mesoporous silica nanoparticles (MSN) with nanovalves or derived coatings have widely been used for triggered and targeted drug delivery in the past. Anticancer drugs can be loaded into the pores of MSN, enabling controlled drug release. In this work, UCNPs were coated with a mesoporous silica shell yielding UCNP@MSN core shell nanoparticles which were equipped with thermoresponsive retro Diels Alder nanovalves and then loaded with DOX , a chemotherapeutic agent for melanoma treatmen t (UCNP@MSN DOX) Subsequent DOX release from this drug delivery system was triggered by 980 nm NIR light. Melanoma cells exposed to UCNP@MSN DOX or the NIR laser exhibited no change in ROS production , while the combination of both induced an increase in ROS production. This combination of conditions also induced changes on apoptosis and necrosis levels. These findings underscore the potential use of UCNP @MSN drug delivery systems with thermoresponsive caps as effective drug delivery platforms for melanoma therapy.zeige mehrzeige weniger

Volltext Dateien herunterladen

  • Poster_Parastu Oskoei IBIMED.pdf
    eng

Metadaten exportieren

Weitere Dienste

Suche bei Google Scholar Anzahl der Zugriffe auf dieses Dokument
Metadaten
Autor*innen:Párástu Oskoei
Koautor*innen:J. Nogueira, L.-M. Keller, Elina AndresenORCiD, F. E. Maturi, Bastian Rühle, Ute Resch-GengerORCiD, A. L. Daniel-da-Silva, L. D. Carlos, H. Oliviera
Dokumenttyp:Posterpräsentation
Veröffentlichungsform:Präsentation
Sprache:Englisch
Jahr der Erstveröffentlichung:2025
Organisationseinheit der BAM:1 Analytische Chemie; Referenzmaterialien
1 Analytische Chemie; Referenzmaterialien / 1.0 Abteilungsleitung und andere
1 Analytische Chemie; Referenzmaterialien / 1.2 Biophotonik
DDC-Klassifikation:Naturwissenschaften und Mathematik / Chemie / Analytische Chemie
Technik, Medizin, angewandte Wissenschaften / Ingenieurwissenschaften / Ingenieurwissenschaften und zugeordnete Tätigkeiten
Freie Schlagwörter:Cellular uptake; Doxorubicin; Folate; Lanthanide; Ligand; Mesoporous silica; Nano; Nanomedicine; Particle; Surface chemistry; Toxicity; Triggered release; Upconversion; pH
Themenfelder/Aktivitätsfelder der BAM:Chemie und Prozesstechnik
Chemie und Prozesstechnik / Chemische Charakterisierung und Spurenanalytik
Material
Material / Advanced Materials
Umwelt
Veranstaltung:VII iBiMED Symposium
Veranstaltungsort:Aveiro, Portugal
Beginndatum der Veranstaltung:23.05.2025
Enddatum der Veranstaltung:24.05.2025
Verfügbarkeit des Dokuments:Datei im Netzwerk der BAM verfügbar ("Closed Access")
Datum der Freischaltung:15.10.2025
Referierte Publikation:Nein
Einverstanden
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.